

Tumour expression
log2 relative miRNA level
5
0
-5
-10
Pleura
MPM
Cell lines
miRNA level
[relative to MeT-5A]
0
-10
-20
-30
-40
-50
H28
H226
H2052
H2452
MSTO-211H
MM05
Ren
miR-16
miR-15a
miR-15b
miR-195
miR-103
miR-107

FIG. 1



***Asbestos exposure 1μM Chrysotile
log10 miRNA level
relative to untreated
10
1
0.1
0.01
0
10
20
30
40
50
60
70
80
90
100
110
miR-16
miR-15a
miR-15b
miR-195
miR-103
miR-107

FIG. 2



5 nM ctrl
5 nM miR-16
5 nM miR-15a
5 nM miR-15b
RFU/s
Time [h]
H28
MeT-5A
MM05
MSTO
H2052
0
48
72
96
120
10000
20000
30000
40000
60000

FIG. 3



A
Cell viability
[% of untreated]
100
80
60
40
20
0
0.01
0.1
1
10
miR mimic (nM)
miR-16
con15/107.1
con15/107.2
con15/107.3
con15/107.4
B
Cell viability
[% of untreated]
100
80
60
40
20
0
0.1
1
10
100
miR mimic (nM)
ctrl mimic
miR-16
con15/107.1
con15/107.2
con15/107.3
con15/107.4

FIG. 4



A
H28
MSTO-211H
Fold change
[compared to ctrl transfected]
0
-5
-10
-15
-20
-25
-30
ACTR1A
ASPH
BCL2
BMI1
CALU
CARD8
CCND1
CCNE1
CDK6
CPD
DICER1
HMGA1
HSP90B1
IKBKB
JUN
MSH2
RECK
SON
TRIM2
VEGFA
WNT4
WWC1
B
5 nM miR-16 mimic
1 nM miR-16 mimic
5 nM ctrl mimic
BCL2
ß-actin
5 nM miR-16 mimic
1 nM miR-16 mimic
5 nM ctrl mimic
CCND1
ß-actin

FIG. 5




A
B
C
D
E
F
Cell viability
[% of untreated]
Gemcitabine [nM]
Pemetrexed [nM]
0.1
1
10
100
1000
0
20
40
60
80
100
120

FIG. 6


2x10^9 VectEDVmiR-16, 4x per week
Saline
Scrambled
miR-16
Tumour volume (mm^3)
Time (days)



1x10^9 VectEDVmiR-16 1, 2 or 4x per week
saline
VectEDV (4)
VectEDVmiR-16 (1)
VectEDVmiR-16 (2)
VectEDVmiR-16 (4)
VectEDVmiR-ctrl (1)
VectEDVmiR-ctrl (2)
VectEDVmiR-ctrl (4)
Tumour volume (mm^3)
Time (days)

FIG. 7



Effect of VectEDV con15/107.2 on tumour growth
Tumour volume (mm³)
300
250
200
150
100
50
0
saline
VectEDV miR-ctrl
Vect EDV miR-16
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Days post xenograft

FIG. 8